Global Information
회사소개 | 문의

심부정맥 혈전증(DVT) : 파이프라인 리뷰

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 192548
페이지 정보 영문 41 Pages
가격
US $ 2,000 ₩ 2,296,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,592,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,888,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심부정맥 혈전증(DVT) : 파이프라인 리뷰 Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018
발행일: 2018년 08월 페이지 정보 : 영문 41 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

심부정맥 혈전증이란 인체 심부(깊은 부위)의 정맥에 생기는 혈전을 가리키며, 주로 종아리 및 대퇴의 대정맥에서 발생합니다. 주요 증상으로 붉은 빛을 띠는 피부 변색 및 하지통, 하지 종창(부종), 피부 온도 상승 등을 들 수 있습니다. 질병 소질에는 연령 및 흡연, 선천성 혈전 장애, 외상 또는 외과 수술흔, 암, 염증성 장질환, 심부전 등이 포함됩니다. 주요 치료제에는 혈전 용해제 및 항응고제 등이 있습니다.

세계 각국에서의 심부정맥 혈전증(DVT) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

심부정맥 혈전증(DVT) 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

심부정맥 혈전증(DVT) : 기업에서 개발중인 치료제

심부정맥 혈전증(DVT) : 대학/기관에서 연구중인 치료제

심부정맥 혈전증(DVT) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

심부정맥 혈전증(DVT) : 기업에서 개발중인 제품

심부정맥 혈전증(DVT) : 대학/기관에서 연구중인 제품

심부정맥 혈전증(DVT) 치료제 개발에 참여하고 있는 기업

  • 3SBio Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Generex Biotechnology Corporation
  • Laboratorios Farmaceuticos Rovi, S.A.

심부정맥 혈전증(DVT) : 치료제 평가

  • 단일요법 제품
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

심부정맥 혈전증(DVT) : 최근 파이프라인 동향

심부정맥 혈전증(DVT) : 휴지중인 프로젝트

심부정맥 혈전증(DVT) : 개발이 중지된 제품

심부정맥 혈전증(DVT) : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 16.07.26

List of Tables

  • Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Deep Vein Thrombosis (DVT) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
  • Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Deep Vein Thrombosis (DVT) - Pipeline by GlycoMimetics Inc, H2 2018
  • Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2018
  • Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2018
  • Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018, provides an overview of the Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline landscape.

Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease and heart failure. Treatment includes thrombolytic and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Deep Vein Thrombosis (DVT) - Overview
    • Deep Vein Thrombosis (DVT) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Deep Vein Thrombosis (DVT) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
    • Dong-A Socio Holdings Co Ltd
    • F. Hoffmann-La Roche Ltd
    • GlycoMimetics Inc
    • Laboratorios Farmaceuticos Rovi SA
  • Deep Vein Thrombosis (DVT) - Drug Profiles
    • Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-20201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enoxaparin sodium biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Heparin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • uproleselan sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Deep Vein Thrombosis (DVT) - Dormant Projects
  • Deep Vein Thrombosis (DVT) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research